Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED | N.MMED.WA | N.MMED.WS

Healthcare
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen... see more

Recent & Breaking News (NDAQ:MNMD)

MindMed Board is Trippin': Significant Investor Calls for Termination of Highly Dilutive Equity Offering and Pledges to Hold Board and Management Accountable through Activist Campaign

PR Newswire September 28, 2022

MindMed Announces Pricing of Public Offering of Common Shares and Warrants

PR Newswire September 27, 2022

MindMed Announces Proposed Public Offering of Common Shares

PR Newswire September 27, 2022

MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances

PR Newswire September 20, 2022

MindMed Announces Compliance with Nasdaq Listing Requirements

PR Newswire September 14, 2022

MindMed Announces Positive Results from Collaborators' Placebo-Controlled Investigator-Initiated Trial Published in Peer-Reviewed Journal

PR Newswire September 8, 2022

MindMed to Participate in H.C. Wainwright Global Investment Conference

PR Newswire September 7, 2022

MindMed Completes 1-for-15 Reverse Share Split

PR Newswire August 26, 2022

MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

PR Newswire August 25, 2022

IIROC Trade Resumption - MMED

Canada NewsWire August 23, 2022

IIROC Trading Halt - MMED

Canada NewsWire August 23, 2022

MindMed Strengthens Board with Appointment of Two New Independent Directors

PR Newswire August 12, 2022

MindMed Reports Second Quarter 2022 Financial Results and Business Highlights

PR Newswire August 11, 2022

MindMed Co-Founder Dr. Scott Freeman Proposes Value Enhancement Plan

PR Newswire August 11, 2022

MindMed Board of Directors Approves Reverse Share Split

PR Newswire August 4, 2022

MindMed to Host Earnings Call to Discuss Second Quarter 2022 Financial Results and Provide Business Update

PR Newswire August 4, 2022

MindMed to Participate in the Canaccord Genuity 42nd Annual Growth Conference

PR Newswire August 2, 2022

MindMed Announces Completion of Share Redesignation

Canada NewsWire June 30, 2022

Mindmed Announces Voting Results for Annual General and Special Meeting

PR Newswire June 1, 2022

MindMed to Participate in the Jefferies Global Healthcare Conference

PR Newswire June 1, 2022